Elexacaftor / tezacaftor / ivacaftor vs lumacaftor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Cystic Fibrosis
Shared mechanism: CFTR · full Cystic Fibrosis pipeline
Elexacaftor / tezacaftor / ivacaftor · Trikafta
Marketed by Vertex Pharmaceuticals
NCT03525444 · Phase 3 · completed
Trial 1 in the TRIKAFTA label was a 24-week, randomized, double-blind, placebo-controlled Phase 3 trial in 405 people aged 12 and older with one F508del variant and a minimal function variant. The single primary endpoint was the absolute change in percent predicted FEV1 at Week 4. TRIKAFTA improved it by 13.8 percentage points more than placebo (95% CI 12.1 to 15.4, P<0.0001), so the primary endpoint was met. Sources: the FDA label (TRIKAFTA) and the CT.gov posted results.
Next expected readout: April 2027 · NCT05331183 (registry estimate)
Reported efficacy
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline at Week 4): Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). (met)
Result source: NCT03525444
lumacaftor · Orkambi
Marketed by Vertex Pharmaceuticals
NCT01807949 · Phase 3 · completed
The trial was randomized, double-blind, placebo-controlled, and included 563 participants. The hard clinical primary endpoint, change in percent-predicted FEV1, was significantly better with both lumacaftor/ivacaftor regimens than placebo: the treatment differences were 2.62 percentage points (p=0.0004) and 3.00 percentage points (p<0.0001).
No aligned efficacy figure on record for this race.
Results for Cystic Fibrosis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
lumacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elexacaftor / tezacaftor / ivacaftor's landscape · lumacaftor's landscape